App-Quantinova.ai

A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).

Molly Jameson - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Prednisolone

Optimising bone health management in advanced prostate cancer: A comparative cohort study.

Anthony Waton - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.

Michael J. Morris - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

Eleni Efstathiou - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

CB-7598

Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Elena Castro - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

CB-7598

Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Teresa Alonso Gordoa - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Cabazitaxel

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.

Rahul Raj Aggarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Pembrolizumab

A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).

Irbaz Bin Riaz - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

N/A

Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT.

Ray Manneh Kopp - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

N/A

Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

Adam B Weiner - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.

Christopher Sweeney - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

CB-7598

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Enzalutamide

A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.

Francisco Gonzalez - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Androgen Tear

CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.

Simon J. Crabb - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Prednisolone

Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Arun Azad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Adenosine

PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.

Nicholas John Van As - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Bladder dysfunction

Androgen Tear

10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016).

Isabel Syndikus - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

The profile study: Prostate cancer screening in men of Black African and African Caribbean ancestry—Early results.

Netty Kinsella - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.

Samuel Tremblay - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Choline bitartrate

Filters

45280 Abstracts